A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Conditions

• Non-Segmental Vitiligo (NSV)
• Vitiligo

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• LY4005130 — DRUG
  Administered IV
• Placebo — DRUG
  Administered IV

Study Details

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.

Key Dates

First listed

Apr 16, 2026

Start date

Apr 14, 2026

Status verified

Jul 2026

Primary completion

May 31, 2027

Completion

Sep 30, 2027

Study Design

Enrollment

66 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: LY4005130
  LY4005130 administered intravenously (IV)
• Placebo Comparator: Placebo
  Placebo administered IV

Primary Outcome Measure

Percentage of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI) 75 [ Time Frame: Week 24 ]

Central Contacts

• Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  1-317-615-4559
  [email protected]
• Physicians interested in becoming principal investigators please contact
  [email protected]

Locations (18)

Find similar trials in Phoenix, AZ

Related Studies

• PPDTM CorEvitasTM Vitiligo Drug Safety and Effectiveness Registry for Adults & Adolescents
  Enrolling By Invitation · CorEvitas · Waltham, Massachusetts
• The Gut and Skin Microbiome in Vitiligo Disease Progression
  Recruiting · Northwestern University · Chicago, Illinois